Investment News

BroadOak portfolio company Reaction Biology Corporation was acquired by Cobepa. Reaction Biology is a leading contract research organization (CRO) that provides drug discovery services to over 1,800 biopharmaceutical customers worldwide. Reaction's capabilities include functional biochemical assays, compound screening, a wide range of mechanistic and biophysical studies,...

An investor group led by BroadOak Capital Partners acquired Particle Dynamics from Edgewater Capital Partners. Particle Dynamics is a global leader in particle processing, delivery technologies, and finished dose manufacturing for the pharmaceutical, over-the-counter, and nutraceutical markets. The full press release is below. Particle Dynamics Announces Sale...

Single-use bioreactor manufacturer, PBS Biotech, recently closed a private $10M funding round with BroadOak Capital Partners. The financing will enable the company to expand and industrialize its portfolio of single-use bioreactor systems and contract process development services. The full press release is below. PBS Biotech Raises $10M...

BroadOak portfolio company Vigene Biosciences was acquired by Charles River Laboratories. Vigene Biosciences is a leading CDMO providing viral vector manufacturing services for the cell and gene therapy market. The full press release is below. Charles River Laboratories Completes Acquisition of Vigene Biosciences WILMINGTON, Mass.–(BUSINESS WIRE)–Jun. 29, 2021–...

Genomenon announced that it has completed a $5.3M financing round in the company. The financing will enable the company to expand its commercial operations, which serve genetic testing labs, hospitals, pharmaceutical and biopharma companies. The full press release is below. Genomenon Completes $5.3M Financing Round AI-Driven Genomics Company...